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Abstract 
Obestatin is a 23 amino acid, ghrelin gene-derived peptide hormone produced in the stomach 
and a range of other tissues throughout the body. While it was initially reported that obestatin 
opposed the actions of ghrelin with regards to appetite and food intake, it is now clear that 
obestatin is not an endogenous ghrelin antagonist of ghrelin, but it is a multi-functional 
peptide hormone in its own right. In this review we will discuss the controversies associated 
with the discovery of obestatin and explore emerging central and peripheral roles of 
obestatin, roles in adipogenesis, pancreatic homeostasis and cancer.  
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1.0 Introduction 
A little more than a decade ago, Kojima and colleagues successfully isolated the 28 amino acid 
growth hormone stimulating peptide, ghrelin, from the stomach (Kojima et al., 1999). As reviewed in 
this special issue of Molecular and Cellular Endocrinology, the discovery of ghrelin sparked a large 
number of studies investigating the role of ghrelin and its receptor in disease. In this review article, we 
will highlight what is known about the recently discovered ghrelin gene-derived peptide, obestatin  
 
2.0 The controversial discovery of obestatin 
Using comparative genomics analysis, Zhang and colleagues revealed that the ghrelin gene region 
that encodes the 66 amino acid, C-terminal region of preproghrelin contained a conserved region 
flanked by convertase cleavage sites, hinting that it may harbour a peptide hormone (Zhang et al., 
2005). Indeed, they found that a 23 amino acid peptide, obestatin, was derived from this region 
(Figure 1) and it was named obestatin (derived from obese and statin) to indicate that it was 
anorexigenic, opposing the function of ghrelin on food intake (Zhang et al., 2005). Obestatin is 
thought to arise through the post-translational cleavage of the ghrelin preprohormone (Zhang et 
al., 2005). It is also possible that novel, specific obestatin-coding transcripts may be translated 
(Seim et al., 2007), although the contribution of these transcripts to obestatin peptide expression 
may be negligible (Volante et al., 2009). Like ghrelin, the stomach is the primary site of obestatin 
expression (Zhang et al., 2005), and obestatin is produced in the same endocrine cell type as 
ghrelin (Granata et al., 2008; Gronberg et al., 2010; Gronberg et al., 2008; Guo et al., 2008; 
Morash et al., 2010; Tsolakis et al., 2009; Volante et al., 2009; Zhao et al., 2008). This finding 
suggested that obestatin was an endocrine gut hormone, primarily acting on the brain (Figure 
2).  
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While the initial discovery of obestatin was an exciting finding in the ghrelin field, it has 
since met with some controversy, particularly with regards to its effect on food intake. The 
original study reporting the discovery and function of obestatin demonstrated that the 
intraperitoneal and intracerebroventricular injections of obestatin inhibited food intake and 
reduced body weight in mice (Zhang et al., 2005). The effects of obestatin on feeding have 
been confirmed by independent investigators (Bresciani et al., 2006; Brunetti et al., 2010; 
Brunetti et al., 2009; Green et al., 2007; Nagaraj et al., 2008; Nagaraj et al., 2009; Zhang et 
al., 2008), however, the majority of studies suggest that obestatin does not have anorexigenic 
effects, regardless of injection site (Bassil et al., 2007; Chartrel et al., 2007; De Smet et al., 
2007; Gourcerol et al., 2006; Holst et al., 2007; Kobelt et al., 2008; Lauwers et al., 2006; 
Mondal et al., 2008; Nogueiras et al., 2007; Samson et al., 2007; Sibilia et al., 2006; 
Tremblay et al., 2007; Unniappan et al., 2008; Van Dijck et al., 2009; Yamamoto et al., 2007; 
Zizzari et al., 2007). The initial description of obestatin also reported that it inhibited 
gastrointestinal motility (Zhang et al., 2005) (Figure 2), however, a number of subsequent 
studies failed to replicate this effect (Bassil et al., 2007; Chen et al., 2008; Chen et al., 2010; 
Depoortere et al., 2008; Gourcerol et al., 2006; Yamamoto et al., 2007). Recent studies by 
Inui and colleagues, however, demonstrated that intravenously administered obestatin could 
inhibit gastrointestinal motility, acting via corticotropin-releasing factor (CRF) receptors in 
the hypothalamic nuclei of the brain (Ataka et al., 2008; Fujimiya et al., 2008). Results in 
obesity have also been inconsistent, with both elevations in obestatin levels (Reinehr et al., 
2008; Vicennati et al., 2007) and reductions in plasma obestatin (Fontenot et al., 2007; Gao et 
al., 2010; Gao et al., 2008) associated with obesity and overweight in different studies 
(Hassouna et al., 2010). The large number of divergent observations regarding the actions of 
obestatin may have arisen as a result of major, or perhaps subtle differences in the various in 
vivo and in vitro experimental models employed to date. Conflicting results in the obestatin 
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field may also partly be due to the lack of stability of the obestatin peptide and its short half-
life (Vergote et al., 2008). It is clear that much research is needed to clearly define the role of 
obestatin as a hormone involved in body weight regulation and gastrointestinal motility. 
 Obestatin may also have other effects unrelated to food intake including emerging roles in 
memory improvement and reduction of anxiety (Carlini et al., 2007) and regulation of 
metabolism and sleep during torpor (mediated centrally by acting on the brain) (Szentirmai et 
al., 2009; Szentirmai and Krueger, 2006). Obestatin may also inhibit thirst (Samson et al., 
2007; Samson et al., 2008) (Figure 2), although this effect was not observed in an 
independent study (Van Dijck et al., 2009). Like ghrelin, obestatin may play an 
immunomodulatory role and it protects against the development of pancreatitis in a curulein-
induced rat model (Ceranowicz et al., 2009). 
It was initially reported that GPR39 (G-protein coupled receptor 39), a member of the ghrelin 
receptor-family, was the obestatin receptor (Zhang et al., 2008; Zhang et al., 2005). Studies by 
other research groups have failed to reproduce these findings, however, and it is now appreciated 
that GPR39 is not a cognate receptor for obestatin (Chartrel et al., 2007; Holst et al., 2007; 
Lauwers et al., 2006; Yasuda et al., 2007). It was recently reported that obestatin binds the GLP-
1R (glucagon-like peptide 1 receptor) in cultured -cells (Granata et al., 2008), however, a 
subsequent study showed that obestatin did not bind GLP-1R, nor displace the GLP-1 ligand, in 
GLP-1R overexpressing cells (Unniappan et al., 2008). Nevertheless, it is clear from numerous 
studies that obestatin binds and activates a G-protein coupled receptor, ultimately stimulating 
extracellular signal-regulated kinase (ERK 1/2) (Alloatti et al., 2010; Alvarez et al., 2009; 
Camina et al., 2007; Dun et al., 2006; Gurriaran-Rodriguez et al., 2010; Meszarosova et al., 2008; 
Pazos et al., 2009; Pazos et al., 2007).  
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As obestatin is a gut hormone (produced in the stomach), obestatin may act as an endocrine 
hormone and may circulate in the blood to reach the brain through the blood brain barrier, it 
could signal to the brain by affecting primary afferent neurons, or both. Unexpectedly, 
obestatin rapidly degrades in the plasma and, unlike ghrelin, it is not able to cross the blood-
brain barrier by a saturable transport system (Pan et al., 2006; Vergote et al., 2008; Zizzari et 
al., 2007). Since the obestatin receptor has not been identified, it is currently difficult to 
dissect how peripheral obestatin may control central systems, such as feeding. There is some 
evidence, however, that obestatin, like ghrelin, may stimulate vagal afferent (sensory) 
pathways from the gut. For example, vagotomy abolished the stimulation of pancreatic juice 
secretion from the exocrine pancreas by intravenously administered obestatin (Kapica et al., 
2008; Kapica et al., 2007). The vagal afferent pathway may, therefore, play a role in 
gastrointestinal motility induced by obestatin (Ataka et al., 2008; Fujimiya et al., 2008). 
The detection of obestatin in biological samples has proven problematic and reproducible and 
consistent data has been lacking (Hassouna et al., 2010). Measurements of obestatin levels in 
plasma and tissues should, therefore, be interpreted with caution. There is some doubt 
regarding the results of current antibody-based detection methods that may not be specific for 
obestatin (Bang et al., 2007; Mondal et al., 2008) and immunohistochemical methods are 
unable to distinguish between obestatin and its precursor form, proghrelin. There is also a 
lack of international assay standards for obestatin, putative obestatin carrier proteins could 
interfere with obestatin antisera, and sampling and pulsatile variations could lead to 
differences in levels of obestatin measured (Hassouna et al., 2010). Some studies have failed 
to detect significant amounts of obestatin in the serum and its role as an endocrine hormone 
has been questioned (Bang et al., 2007; Mondal et al., 2008; Pemberton and Richards, 2008).   
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The physiological significance of plasma obestatin levels and the effects on food intake are 
currently controversial (Gao et al., 2008). While it is recognised that there are reservations 
regarding obestatin measurements, the plasma ratio of ghrelin to obestatin may be a more 
informative measure than levels of obestatin alone and this ratio could prove a useful 
biomarker for some disease states. The ghrelin to obestatin ratio is reduced in a number of 
diseases, including inflammatory bowel disease (Alexandridis et al., 2009), chronic atrophic 
gastritis (not associated with Helicobacter infection) compared to controls (Gao et al., 2008) 
and in Chinese patients infected with Helicobacter pylori (Gao et al., 2009), indicating that 
obestatin may play a role in the pathogenesis of these diseases. Obestatin may also play a role 
in the pathogenesis of metabolic diseases, including anorexia nervosa, where obestatin blood 
levels are divergent (Germain et al., 2010; Monteleone et al., 2008; Sedlackova et al., 2010). 
The ghrelin to obestatin ratio has also been reported as elevated in studies of obese patients 
(Guo et al., 2007) and this ratio could prove to be important in the regulation of energy 
metabolism (Hassouna et al., 2010).  
3.0 Emerging peripheral effects of obestatin 
Although the majority of obestatin is produced by the stomach, the obestatin peptide has been 
reported to be expressed in a range of peripheral tissues, including the pancreas (Granata et 
al., 2008; Gronberg et al., 2008; Guo et al., 2008; Volante et al., 2009; Zhao et al., 2008), 
liver (Guo et al., 2008), testis (Dun et al., 2006), mammary gland (Gronberg et al., 2010; 
Gronberg et al., 2008), thyroid (Karaoglu et al., 2009), and lung (Volante et al., 2009). This 
may indicate that obestatin has local autocrine/paracrine roles in addition to its actions as an 
endocrine hormone. As noted, obestatin is an orphan ligand and the search for the obestatin 
receptor is still ongoing, however, binding sites for the obestatin peptide have been identified 
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in the pancreas, heart, white adipose tissue and other tissues (Alloatti et al., 2010; Granata et 
al., 2008; Iglesias et al., 2007; Zhang et al., 2008).  
3.1 The endocrine pancreas  
Obestatin may be an important regulator of endocrine pancreatic function and -cell survival. 
In the endocrine pancreas, obestatin is co-expressed in the same cell type as ghrelin, 
suggesting a role for obestatin in pancreatic function (Granata et al., 2008; Granata et al., 
2010; Gronberg et al., 2008; Volante et al., 2009; Walia et al., 2009; Zhao et al., 2008). 
Obestatin is secreted by pancreatic cell lines and human pancreatic islet cells where it binds 
to high affinity binding sites (Granata et al., 2008). Obestatin may play a role as an 
autocrine/paracrine growth and survival factor in the pancreatic islets (Granata et al., 2010; 
Granata et al., 2008) and the maintenance of pancreatic -cell mass is important for 
pancreatic endocrine function and glucose balance. Obestatin increases cell proliferation and 
promotes cell survival in human isolated pancreatic islet cells and in the HIT-T15 and INS-IE 
pancreatic -cell lines (Granata et al., 2008). Chronic obestatin treatment, like ghrelin, 
promotes the maintenance of islet size and -cell mass in vivo, in a streptozotocin (STZ)-
induced neonatal rat model of diabetes (Granata et al., 2010).  
Apoptosis is a key process causing -cell death in diabetes mellitus and is often associated 
with pro-inflammatory cytokines (Granata et al., 2010). In pancreatic islet cell lines, obestatin 
protected against apoptosis stimulated by pro-inflammatory cytokines, and apoptosis 
stimulated by serum widthdrawal (Granata et al., 2008). Interestingly, D-(lys-3) GHRP-6 (a 
ghrelin receptor antagonist) and treatment with an anti-ghrelin antibody inhibited these 
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effects in response to obestatin treatment, suggesting that there may be cross-talk between the 
actions of obestatin and ghrelin in the endocrine pancreas (Granata et al., 2008).  
The role of obestatin in stimulating insulin secretion is currently somewhat controversial, 
with some studies demonstrating that obestatin inhibits insulin secretion, stimulates secretion 
or has no effect on insulin secretion (Granata et al., 2008). Obestatin may play a role in 
glucose metabolism in humans and an inverse relationship has been demonstrated between 
obestatin and insulin levels (Gao et al., 2008; Li et al., 2010; Lippl et al., 2008). In isolated 
human pancreatic islets, obestatin has been demonstrated to increase insulin secretion and 
activate genes associated with insulin synthesis (Granata et al., 2008). In contrast, in isolated 
mouse and rat islets, obestatin inhibited insulin release in a dose dependent manner (Qader et 
al., 2008) and in an in vivo rat model, obestatin inhibited glucose-stimulated insulin release 
(Ren et al., 2008). Obestatin was reported to have no effect on glucose or insulin levels under 
basal or fasting conditions in rats and mice (Green et al., 2007; Ren et al., 2008). Another 
study indicated that obestatin may have dual effects on insulin release in response to glucose 
in perfused rodent islets, enhancing insulin release at low obestatin concentrations and 
inhibiting insulin release at higher concentrations when glucose levels were maintained at a 
constant level (Egido et al., 2009). In this study, -cells were more responsive to obestatin 
when glucose levels were high than when glucose levels were low (Egido et al., 2009). In the 
STZ-induced rat model of diabetes, obestatin prevented the development of diabetes mellitus 
symptoms and improved glucose metabolism (Granata et al., 2010).   
In isolated human pancreatic islets, obestatin upregulates the expression of a range of genes 
associated with cell survival, -cell mass, growth and differentiation and glucose metabolism 
(Granata et al., 2008). The expression of the transcript for the transcription factor Pdx1 is 
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upregulated in isolated human pancreatic islets and in STZ neonatal rat diabetic islets after 
obestatin treatment (Granata et al., 2008; Granata et al., 2010). Pdx1 plays an important role 
in maintaining -cell mass and in stimulating the differentiation of -cells in the pancreas 
(Granata et al., 2010). The ability of obestatin to regulate genes that are important in -cell 
function, increasing -cell mass by stimulating cell proliferation and protecting against 
apoptosis mediated by pro-inflammatory cytokines, indicates that it could be useful in the 
future development of therapeutics for diabetes mellitus (Granata et al., 2008). Studies into 
the role of obestatin in the pancreas are sure to reveal important insights into the 
pathobiology of diabetes, pancreatitis and pancreatic cancer and obestatin shows promise as a 
future target for the development of novel therapeutics for diabetes mellitus (Granata et al., 
2010).   
3.2 Adipose tissue 
While the role of obestatin in obesity and related pathologies that affect adipose 
homeostasis remains controversial, preliminary studies indicate that obestatin may indeed 
be a functional peptide in adipose tissue. It is now well-established that adipose tissue is an 
endocrine organ that can secrete peptides and express receptors for a range of peptide 
hormones (Galic et al., 2010). Peripheral administration of obestatin induced expression of 
the gene c-fos, an early response gene that undergoes rapid transcriptional activation by 
growth factors and mitogens, in white adipose tissue and cultured mouse adipocytes (Zhang 
et al., 2008). Moreover, injection of obestatin significantly decreased the levels of the gene 
ABCA1 (ATP-binding cassette A1), a key cholesterol transporter, in white adipose tissue in 
cows. While this suggests a role for obestatin in cholesterol transport (Grala et al., 2010),  
this hypothesis remains to be investigated. A recent report employing transgenic mice 
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expressing the full-length preproghrelin peptide indicates that adipose tissue does not 
secrete obestatin into the blood (Zhang et al., 2008). Very recently, it was reported that 
adipocytes secrete obestatin and that it promotes adipogenesis in an autocrine/paracrine 
manner (Gurriaran-Rodriguez et al., 2010). In an elegant set of experiments, obestatin 
secreting 3T3-L1 preadipocytes were subjected to anti-obestatin antibody and preproghrelin 
gene silencing treatments, which demonstrated that obestatin directly regulates adipocyte 
differentiation (Gurriaran-Rodriguez et al., 2010). These findings indicate that 
autocrine/paracrine obestatin, as well as circulating obestatin from the stomach, or other 
tissues, may act on obestatin receptors in adipose tissue to regulate growth and 
differentiation.  
3.3 The renal system 
The role of obestatin (and indeed ghrelin) in the renal system is not well-established. 
Interestingly, it has been reported that normal kidney tissue expresses comparable levels of 
ghrelin to the stomach (Dagli et al., 2009; Mori et al., 2000), suggesting that the kidney can 
produce high levels of ghrelin gene derived peptides, such as obestatin. The potential role of 
obestatin in energy balance indicates that it may play a role in chronic kidney disease, which 
is characterised by anorexia and muscle wasting (or cachexia) (Cheung and Mak, 2010; 
Mafra et al., 2010). Obestatin levels are elevated in plasma of patients with chronic kidney 
disease and in patients with kidney failure (end stage renal disease) (Aygen et al., 2009; 
Buscher et al., 2010). Haemodialysis of chronic kidney disease patients resulted in lower 
plasma obestatin levels (Mafra et al., 2009). No substantiated reports on obestatin function in 
the renal system are available to our knowledge, however the current data suggests that 
normal renal function is necessary for clearance of the approximately 2.5 kDa obestatin 
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peptide from the circulation.  
3.4 Obestatin in the cardiovascular system 
Elevated obestatin levels have been reported in cachexic patients with congestive heart failure 
(Xin et al., 2009), but not in non-cachexic congestive heart failure patients (Xin et al., 2009), 
or patients with ischaemic heart disease (Ozbay et al., 2008). Moreover, binding sites for 
obestatin have been identified in the heart (Alloatti et al., 2010) and obestatin-induced 
contractions of ex vivo hearts from frogs are blocked by a protein kinase A inhibitor, 
indicating that obestatin influences -adrenergic receptors of cardiac muscle cells (Xin et al., 
2009). Exogenous obestatin has no effect on cell cycle or viability in the HL-1 cardiac muscle 
cell line (Iglesias et al., 2007), however, a recent study showed that obestatin plays a role in 
protecting myocardial function following reperfusion injury of cardiac muscle cells (Alloatti 
et al., 2010).  
 
Obestatin may also play a role in regulating blood pressure. The ghrelin to obestatin ratio and 
obestatin levels were reduced in patients with mild to moderate high blood pressure in one 
study (Li et al., 2010) and obestatin has also been shown to have a negative correlation with 
systolic blood pressure in humans (Anderwald-Stadler et al., 2007). In contrast, in the 
spontaneously hypertensive rat, there is a positive correlation between obestatin levels and 
systolic blood pressure and obestatin levels are significantly higher in these rats compared to 
normal Wistar-Kyoto rats (Li et al., 2010). Similarly, obestatin levels were elevated in 
pregnant women with pregnancy-induced hypertension compared to women with normal 
pregnancies (Ren et al., 2009). While it appears that obestatin may play a role in the 
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regulation of blood pressure, intravenous injection of obestatin did not alter blood pressure in 
spontaneously hypertensive rats (Li et al., 2009).  
 
3.5 Obestatin as a growth factor of peripheral tissues 
Evidence is rapidly emerging that obestatin (acting through an unknown receptor), may play 
a similar autocrine/paracrine role to ghrelin (Seim et al., 2010) in a variety of cellular 
systems. As discussed, exogenous obestatin stimulates proliferation of pancreatic -cells and 
isolated human pancreatic islet cells (Granata et al., 2008) (section 3.1) and promotes 
adipogenesis (Gurriaran-Rodriguez et al., 2010) (section 3.2). Exogenous obestatin also 
stimulates cell proliferation in retinal pigment epithelial cells (Camina et al., 2007), but 
inhibits proliferation in the regenerating adrenal cortex (Rucinski et al., 2010). Immunoblot-
based assays show that obestatin also alters the levels of proteins involved in proliferation 
and apoptosis in ovarian granulosa cells, suggesting that the peptide may regulate turnover 
and remodelling of ovarian follicles (Meszarosova et al., 2008).  
Chondrocytes have binding sites for obestatin and secrete obestatin, which inhibits 
proliferation in the human C28-I2 rib chondrocyte cell line and in the ATDC5 mouse 
embryonal carcinoma-derived cell line after it has been differentiated into chondrocytes 
(Lago et al., 2007). In contrast to ghrelin, however, obestatin did not modulate known 
markers of chondrocyte metabolism (Caminos et al., 2005; Lago et al., 2007). It would be 
most interesting to examine the role of obestatin in chondrocyte disease states, such as 
chondrosarcoma, in future studies.  
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3.6 Obestatin and cancer  
Finally, obestatin may have a pathophysiological role in cancer. Immunoassay-based studies 
have reported that obestatin levels are higher in the blood of patients with ovarian cancer than 
in normal controls (Markowska et al., 2009). There was no correlation between blood levels 
of obestatin and disease status, however, in prostate cancer (Malendowicz et al., 2009) and 
uterine leiomyoma patients (Markowska et al., 2009). It is likely that obestatin functions 
solely at the autocrine and paracrine level in cancer and systemic levels of the peptide are 
unlikely to reflect levels in the cancer microenvironment. Exogenous obestatin stimulates 
proliferation in the KATO-III gastric cancer cell line (Pazos et al., 2007), but not the AGS 
gastric cancer cell line (where it, on the other hand, stimulates growth hormone release) 
(Pazos et al., 2009). Obestatin also inhibits proliferation of TT-human medullary thyroid 
carcinoma and the endocrine BON-1 pancreatic tumor cell line (Volante et al., 2009). 
Interestingly, immunohistochemical studies suggests that obestatin expression is reduced in 
thyroid and pancreatic tumour tissue and that the obestatin may be specifically downregulated 
by these tumours types in order to circumvent the inhibition of proliferation demonstrated in 
vitro (Volante et al., 2009). Finally, in our laboratory, we have recently demonstrated that 
exogenous obestatin induces cell proliferation by phosphorylating Akt, PKC and ERK1/2 in 
the PC3 prostate cancer cell line (Amorim et al., unpublished observations). We have also 
demonstrated that obestatin is synthesised and secreted by ovarian cancer cell lines in vitro 
(Walpole et al,. unpublished observations). Exogenous obestatin treatment significantly 
increases the migration of ovarian cancer cell lines in culture (Walpole et al,. unpublished 
observations). Taken together, the available evidence shows that obestatin is an 
autocrine/paracrine growth factor in peripheral tissues and may play a role in cancer 
progression. 
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4.0 Conclusion 
In contrast to early suggestions, obestatin is not an endogenous antagonist of ghrelin, but 
recent studies indicate that obestatin is a multi-functional peptide hormone in its own right. 
Obestatin may have important endocrine, autocrine or paracrine roles in a number of tissues 
including pancreas, and adipose tissue and it may play a role in cancer progression. The 
obestatin receptor is yet to be discovered, and this currently limits in vivo and in vitro studies 
and our understanding of obestatin function. The development of more reliable asssays for 
obestatin will also allow this field of research to progress more rapidly and may clarify many 
of the current discrepancies in results. Despite early controversies, we propose that the 
obestatin research field will be as fruitful as the last decade of ghrelin research, and that the 
next few years will identify the obestatin receptor and reveal the potential of obestatin as a 
hormone in its own right with potential as a diagnostic and therapeutic target. In particular, 
we predict that obestatin may play essential roles in cancer progression. 
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Figure 1. Schematic genomic organisation of the human ghrelin gene and the 
preproghrelin coding exons.  
The exons shaded in white indicate extended exons. Exon sizes (bp) are shown above each 
exon. The regions of preproghrelin are indicated by different colours. 
 
Figure 2. Known and putative functions of obestatin 
The effects of obestatin may be endocrine, paracrine, or autocrine. The biological effects may 
be direct, resulting from obestatin binding its receptor on target cells, or indirect. Indirect 
effects can results by obestatin conveying vagal afferent information by interacting with its 
cognate receptor on vagal neurons, or by secretion of other hormones that are able to reach 
the target tissue. 
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